Maximizing Real-World Data: Impact of Cardiovascular Disease on Clinical Outcomes in Rheumatoid Arthritis

Current guidance on rheumatoid arthritis (RA) stresses the importance of considering Clinical Outcomes in RAcomorbidity when assessing disease activity and making clinical decisions.1 Comorbidities commonly associated with RA include cardiovascular disease (CVD), lung disease and malignancy.2

The complex relationship between RA and CVD comorbidities

The presence of CVD itself has been shown to increase the risk of death in RA patients by approximately 50%,3 and there is an emerging relationship between RA, CVD and the therapies used to treat them. Continue reading

An Analytical Approach to Enhance Recruitment of Rheumatoid Arthritis Patients

No single blood test or physical finding alone can confirm the diagnosis of rheumatoid arthritis (RA). However, two tests that detect markers of inflammation are often ordered when RA is suspected: erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Other common tests include rheumatoid factor and anti-CCP antibodies.

RA Map

RA patients in the United States

While the test results are clearly valuable to the requesting physician to inform diagnostic decisions, sponsors can also leverage this information to support patient recruitment in an increasingly competitive space. We recently evaluated how de-identified patient data from these common tests run by LabCorp can support sponsors’ clinical trials in rheumatoid arthritis. Continue reading